Dermatitis : contact, atopic, occupational, drug最新文献_第2页

Perineal Vitiligo: A Manifestation of Pinworm Infection.

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-02-10 DOI: 10.1089/derm.2024.0154

Nesrine Ben Salah, Khaoula Trimeche, Hichem Belhadjali, Yasmine Bahri, Monia Youssef, Jameleddine Zili

引用次数: 0

The Heterogeneous Clinical Manifestations of Atopic Dermatitis Across Diverse Patient Populations.

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-02-10 DOI: 10.1089/derm.2024.0197

Joshua Horeczko, Andrew Alexis, Jonathan I Silverberg

引用次数: 0

What Does Long-Term Control in Atopic Dermatitis Look Like?

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-02-10 DOI: 10.1089/derm.2024.0121

Shanthi Narla, Zelma C Chiesa Fuxench, Katrina Abuabara, Lisa A Beck, Raj Chovatiya, Diamant Thaçi, Jonathan I Silverberg

{"title":"What Does Long-Term Control in Atopic Dermatitis Look Like?","authors":"Shanthi Narla, Zelma C Chiesa Fuxench, Katrina Abuabara, Lisa A Beck, Raj Chovatiya, Diamant Thaçi, Jonathan I Silverberg","doi":"10.1089/derm.2024.0121","DOIUrl":"https://doi.org/10.1089/derm.2024.0121","url":null,"abstract":" What defines long-term control in atopic dermatitis (AD) and why is it difficult to measure in AD? Why does long-term control matter? Herein, we critically examine these questions along with the clinical rationale, approaches for assessing long-term control in clinical practice, potential mechanistic underpinnings for AD long-term control, and evidence for long-term control with current systemic AD treatments. Currently, there is limited consensus on how to define flares and long-term control due to AD's heterogeneous nature, and AD being a disorder largely defined by patients' individual experience. An important part of long-term control is disease modification, which is made up of the impact on the disease itself and also its impact on AD's associated comorbidities. By focusing on the multiple facets of long-term control, possible deep/long-term remission or even therapy free remission may be achieved. While there is some research currently available on the long-term efficacy of current AD therapies, larger studies with longer follow-up periods are needed to adequately determine if reduced dosing can be applied to AD patients who have achieved deep/long-term remission. Future directions in AD may involve developing new therapies that target the innate and adaptive immune systems to bring about disease modification.","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increasing Diversity, Equity, and Inclusion in Dermatitis Research: A Dermatitis Journal Call for Action.

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-02-05 DOI: 10.1089/derm.2024.0558

Marjorie E Montañez-Wiscovich

引用次数: 0

Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis. 中重度特应性皮炎患者对曲洛单抗不良反应的预测因素：真实世界分析

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-02-05 DOI: 10.1089/derm.2024.0515

Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

{"title":"Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis.","authors":"Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda","doi":"10.1089/derm.2024.0515","DOIUrl":"https://doi.org/10.1089/derm.2024.0515","url":null,"abstract":"Abstracts: Background: Some patients with moderate-to-severe atopic dermatitis (AD) show insufficient response to treatment with tralokinumab, an anti-interleukin-13 antibody. Identifying predictive factors for poor responders to tralokinumab can help optimize treatment strategies for AD patients. Objective: To identify predictive factors for poor responders to tralokinumab, defined as an investigator's global assessment >2 at week 12 or 24. Methods: A prospective study was conducted from October 2023 to August 2024, including 109 Japanese patients with moderate-to-severe AD. Baseline features were compared between poor responders versus responders at week 12 or 24. Results: Poor responders at week 12 showed higher baseline eczema area and severity index (EASI), lactate dehydrogenase (LDH), and eosinophil-to-lymphocyte ratio (ELR) compared with responders. Poor responders at week 24 had older age, longer disease duration, and higher proportions of previous systemic therapies, previous dupilumab, or previous 15 mg upadacitinib treatment, compared with responders. Conclusions: Higher baseline EASI, LDH, and ELR may predict poor response to tralokinumab at week 12. Older age, longer disease duration, and previous usage of systemic therapy, dupilumab, or 15 mg upadacitinib may predict poor response to tralokinumab at week 24. AD patients with the above features may as well avoid tralokinumab treatment.","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Para-Phenylenediamine-Induced Lichenoid Eruption With Involvement of the Oral Mucosa and Subsequent Contact Leukoderma.

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-01-27 DOI: 10.1089/derm.2024.0249

Karama Sboui, Ines Lahouel, Hichem Belhadjali, Yosra Soua, Monia Youssef, Jameleddine Zili

引用次数: 0

The Patent Blue V Paradox: Hidden Offender, Serial Culprit. 专利蓝 V 悖论：隐藏的罪犯，连环的罪魁祸首。

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-01-27 DOI: 10.1089/derm.2024.0519

Mariana Bragança, Ana Luísa Pinhal, Eunice Dias de Castro, Leonor Carneiro Leão

{"title":"The Patent Blue V Paradox: Hidden Offender, Serial Culprit.","authors":"Mariana Bragança, Ana Luísa Pinhal, Eunice Dias de Castro, Leonor Carneiro Leão","doi":"10.1089/derm.2024.0519","DOIUrl":"https://doi.org/10.1089/derm.2024.0519","url":null,"abstract":" Background: Patent Blue V (PBV) is extensively used in sentinel lymph node identification in cancer surgery, potentially leading to an increased incidence of hypersensitivity reactions. Methods: A retrospective analysis was conducted on patients with suspected PBV hypersensitivity, at our center from 2010 to 2023. Skin prick tests (SPT) were performed on all patients, followed by intradermal tests (IDT) if SPT was negative. Results: Of 160 patients with suspected perioperative hypersensitivity reactions (POH), 15 (9.4%) had received PBV. All patients were female, with a median age of 50 years. None had been previously exposed to PBV. In 2 cases, there was no registry of PBV use. In vivo tests were mostly performed 6-9 months after the index reaction (53%). PBV allergy was confirmed in 80% of cases via positive skin tests (SPT [n = 10] or IDT [n = 2]). In PBV allergic patients, anaphylaxis occurred in 7 patients (58%). A rising incidence of PBV allergy in the POH setting was observed from 2010 to 2023. Conclusions: PBV is a significant allergen in POH, with increasing incidence. SPT is effective and frequent enough for diagnosis, suggesting an IgE-mediated mechanism. Despite its allergenic potential, PBV's clinical utility supports its continued use with appropriate precautions.","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Impact of Allergen Avoidance in Burning Mouth Syndrome: A Case Series.

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-01-23 DOI: 10.1089/derm.2024.0423

Rachel M Seifert, Christopher M Hull, Rosemary A deShazo, Douglas L Powell, Jamie L W Rhoads, John J Zone, Zachary H Hopkins

引用次数: 0

Chlorphenesin-Induced Allergic Contact Dermatitis: An Overlooked Phenomenon? 氯霉素引起的过敏性接触性皮炎：一个被忽视的现象？

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-01-17 DOI: 10.1089/derm.2024.0433

Carlos Manuel Moreira de Nogueira, Catarina Dias Cerqueira, Miguel Ângelo Santos Ribeiro, Teresa Maria Marques Pereira Cabral Ribeiro

引用次数: 0

Thoughts on the Classification of Patch Test Reactions with Focus on the Threshold Between Weak Allergic and Doubtful Reactions. 对斑贴试验反应分类的思考——以弱过敏与可疑反应的阈值为重点。

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-01-16 DOI: 10.1089/derm.2024.0425

Magnus Bruze

引用次数: 0